FDA: Baxter, Salix should revise warning labels

03/23/2008 | Chicago Tribune (tiered subscription model) · Yahoo!

The FDA on Friday recommended new warnings for pediatric use of Suprane, Baxter International's inhaled anesthetic, and Colazal, Salix Pharmaceuticals Ltd.'s anti-inflammatory drug. The agency said Suprane should address cardiac arrest risk following three reported cases among children, while Colazal should have warnings on heart and lung risks that other drugs in the same class carry.

View Full Article in:

Chicago Tribune (tiered subscription model) · Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX